Danish eyewear brand ProDesign unveils its Fall/Winter 2025 collection under the slogan “Details define us.” Staying true to its DNA, the brand explores a refined take on design, balancing formal purity, technical precision, and subtle color work. What’s the guiding principle behind ProDesign FW25? The collection revolves around a central idea: detail as identity. Every […]
EssilorLuxottica has announced its acquisition of RetinAI, a Swiss company specializing in artificial intelligence for eye care. This move strengthens the group’s med-tech ambitions by integrating predictive analytics and large-scale image processing tools into its ecosystem, aimed at healthcare professionals.
What exactly does RetinAI develop for visual health?
RetinAI (Ikerian AG) builds medical data analysis software, including RetinAI Discovery®, an FDA-cleared and CE-marked platform that uses AI algorithms to interpret retinal images. It targets conditions like AMD, glaucoma, and diabetic retinopathy, helping clinicians make faster, more accurate decisions.
How does this acquisition align with EssilorLuxottica’s strategy?
This acquisition furthers EssilorLuxottica’s transformation into a global med-tech player. By integrating RetinAI’s AI into its ecosystem, the group is advancing a more predictive and personalized approach to care, combining diagnostics, research, therapeutic innovation, and surgical excellence. The goal is a fully digital patient journey.
What are the benefits for professionals and patients?
RetinAI's solutions offer healthcare professionals automated analytics based on large biomarker datasets. This enables earlier disease detection, personalized monitoring, and improved clinical outcomes. For patients, it means faster, more accurate eye care.
How does AI accelerate clinical research through RetinAI?
RetinAI works with clinical networks and pharmaceutical companies to optimize R&D. Its models leverage real-world data to streamline trials and drug development, making research more agile and grounded in actual clinical practice.
What does the future look like for RetinAI and EssilorLuxottica together?
RetinAI CEO Carlos Ciller sees this acquisition as a turning point for scaling the company’s impact. For Francesco Milleri, EssilorLuxottica CEO, it represents a strategic lever to reshape global eye care by putting data and AI at the center.
EssilorLuxottica x RetinAI: Why spotlight this acquisition now?
Because it marks a strategic shift toward predictive, data-driven eye care. By acquiring RetinAI, EssilorLuxottica isn’t just forming a partnership—it is cementing its leadership in the future of AI-powered ophthalmic diagnostics.
